Human heart genomic DNA is an essential biological material for investigating the genetic basis of cardiovascular development, inherited cardiomyopathies, arrhythmogenic disorders, ischemic heart disease, and heart failure. Extracted from human cardiac tissue, genomic DNA represents the complete nuclear genome of cardiac cells and is particularly valuable when integrated with matched tissue-specific molecular, genomic, and histopathological analyses. Human heart genomic DNA is widely used in cardiovascular genetics, molecular pathology, functional genomics, and translational research to identify and characterize disease-associated and pathogenic genetic variants, investigate genotype–phenotype relationships, and validate genetic biomarkers. It also supports studies of inherited cardiac disorders involving sarcomeric, desmosomal, ion-channel, and extracellular matrix genes, as well as signaling pathways implicated in myocardial remodeling, cardiac development, and disease progression.

Key Features

• Comprehensive Cardiac Genomic DNA : Contains genomic DNA representing the complete nuclear genome of human cardiac tissue.

• Broad Genomic Workflow Compatibility: Suitable for PCR, qPCR, digital PCR, Sanger sequencing, next-generation sequencing (NGS), whole-genome sequencing (WGS), targeted sequencing, and genotyping.

• Comprehensive Variant Analysis : Supports analysis of single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), and structural variants.

• Supports Cardiovascular Genomics : Compatible with cardiovascular genetics, molecular pathology, functional genomics, translational research, and genetic biomarker discovery.

• Disease-Focused Genomic Investigations : Enables investigation of inherited genetic variation and somatic genomic alterations associated with cardiovascular disease.

Typical Research Applications

• Genetic studies of inherited cardiomyopathies, including hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathy.

• Research on inherited cardiac channelopathies, including long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia.

• Investigation of genetic susceptibility to coronary artery disease, myocardial infarction, congenital heart disease, and heart failure.

• Identification and validation of disease-associated genetic variants, targeted genomic studies, pharmacogenomics, and precision cardiovascular research.

• Integration of genomic data with transcriptomic, epigenomic, proteomic, and histopathological analyses to investigate molecular mechanisms underlying cardiovascular disease.